Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes

Brian J Andonian, David B Bartlett, Janet L Huebner, Leslie Willis, Andrew Hoselton, Virginia B Kraus, William E Kraus, Kim M Huffman, Brian J Andonian, David B Bartlett, Janet L Huebner, Leslie Willis, Andrew Hoselton, Virginia B Kraus, William E Kraus, Kim M Huffman

Abstract

Background: Sarcopenic obesity, associated with greater risk of cardiovascular disease (CVD) and mortality in rheumatoid arthritis (RA), may be related to dysregulated muscle remodeling. To determine whether exercise training could improve remodeling, we measured changes in inter-relationships of plasma galectin-3, skeletal muscle cytokines, and muscle myostatin in patients with RA and prediabetes before and after a high-intensity interval training (HIIT) program.

Methods: Previously sedentary persons with either RA (n = 12) or prediabetes (n = 9) completed a 10-week supervised HIIT program. At baseline and after training, participants underwent body composition (Bod Pod®) and cardiopulmonary exercise testing, plasma collection, and vastus lateralis biopsies. Plasma galectin-3, muscle cytokines, muscle interleukin-1 beta (mIL-1β), mIL-6, mIL-8, muscle tumor necrosis factor-alpha (mTNF-α), mIL-10, and muscle myostatin were measured via enzyme-linked immunosorbent assays. An independent cohort of patients with RA (n = 47) and age-, gender-, and body mass index (BMI)-matched non-RA controls (n = 23) were used for additional analyses of galectin-3 inter-relationships.

Results: Exercise training did not reduce mean concentration of galectin-3, muscle cytokines, or muscle myostatin in persons with either RA or prediabetes. However, training-induced alterations varied among individuals and were associated with cardiorespiratory fitness and body composition changes. Improved cardiorespiratory fitness (increased absolute peak maximal oxygen consumption, or VO2) correlated with reductions in galectin-3 (r = -0.57, P = 0.05 in RA; r = -0.48, P = 0.23 in prediabetes). Training-induced improvements in body composition were related to reductions in muscle IL-6 and TNF-α (r < -0.60 and P <0.05 for all). However, the association between increased lean mass and decreased muscle IL-6 association was stronger in prediabetes compared with RA (Fisher r-to-z P = 0.0004); in prediabetes but not RA, lean mass increases occurred in conjunction with reductions in muscle myostatin (r = -0.92; P <0.05; Fisher r-to-z P = 0.026). Subjects who received TNF inhibitors (n = 4) or hydroxychloroquine (n = 4) did not improve body composition with exercise training.

Conclusion: Exercise responses in muscle myostatin, cytokines, and body composition were significantly greater in prediabetes than in RA, consistent with impaired muscle remodeling in RA. To maximize physiologic improvements with exercise training in RA, a better understanding is needed of skeletal muscle and physiologic responses to exercise training and their modulation by RA disease-specific features or pharmacologic agents or both.

Trial registration: ClinicalTrials.gov Identifier: NCT02528344 . Registered on August 19, 2015.

Keywords: Cytokines; Galectin-3; High-intensity interval exercise; Myostatin; Rheumatoid arthritis; Sacropenic obesity.

Conflict of interest statement

Ethics approval and consent to participate

All participants gave written informed consent. The study was approved by the Duke University Medical Center Institutional Review Board (Pro00064057).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Plasma galectin-3 in rheumatoid arthritis (RA) compared with healthy controls. Graphs comparing plasma galectin-3 in older RA subjects (n = 24; age >55) with older age-, sex-, and body mass index (BMI)-matched controls (n = 12; age >55). *P <0.05 for comparisons between older RA group (age greater than 55) and older controls (age greater than 55)
Fig. 2
Fig. 2
Plasma galectin-3 correlations before and after high-intensity interval training (HIIT). a Scatter plot depicting relationships between change in plasma galectin-3 (y-axis) and change in absolute peak VO2 (x-axis) following exercise training in the rheumatoid arthritis group (n = 12; r = −0.57; P = 0.05). b Scatter plot depicting the Spearman’s correlation coefficient for change in plasma galectin-3 (y-axis) and change in absolute peak VO2 (x-axis) following exercise training in the prediabetes group (n = 9; r = −0.48, P = 0.23), Fisher r-to-z P = 0.81. Abbreviation: VO2 maximal oxygen consumption
Fig. 3
Fig. 3
Body composition correlations in rheumatoid arthritis (RA) and prediabetes. Scatter plot depicting the relationships between (a) change in lean mass (y-axis) and change in muscle myostatin (x-axis) following exercise training in RA (r = −0.39, P = 0.23); (b) change in lean mass and change in muscle myostatin in prediabetes (PD) (r = −0.92, P = 0.0005), Fisher r-to-z P = 0.026; (c) change in lean mass and change in muscle interleukin-6 (IL-6) in RA (r = −0.65; P = 0.023); (d) change in lean mass and change in muscle IL-6 in prediabetes (r = −0.98, P <0.0001), Fisher r-to-z P = 0.0004; (e) change in lean mass and change in muscle IL-1β in RA (r = −0.63; P = 0.049); (f) change in lean mass and change in muscle IL-1β in prediabetes (r = −0.38, P = 0.31), Fisher r-to-z P = 0.516; (g) change in lean mass and change in muscle tumor necrosis factor-alpha (TNF-α) in RA (r = −0.68; P = 0.023); (h) change in lean mass and change in muscle TNF-α in prediabetes (r = −0.82, P = 0.002), Fisher r-to-z P = 0.516; (i) change in body fat percentage and change in muscle TNF-α in RA (r = 0.67; P = 0.022); and (j) change in body fat percentage and change in muscle TNF-α in prediabetes (r = −0.07, P = 0.88), Fisher r-to-z P = 0.095

References

    1. Svensson AL, Christensen R, Persson F, Løgstrup BB, Giraldi A, Graugaard C, et al. Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. BMJ Open. 2016;6:e009134. doi: 10.1136/bmjopen-2015-009134.
    1. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapää-Dahlqvist S, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010;268:578–585. doi: 10.1111/j.1365-2796.2010.02260.x.
    1. Lindhardsen JO, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929–934. doi: 10.1136/ard.2010.143396.
    1. Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014;33:737–748. doi: 10.1016/j.clnu.2014.03.007.
    1. Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum. 2008;59:807–815. doi: 10.1002/art.23719.
    1. Huffman KM, Jessee R, Andonian B, Davis BN, Narowski R, Huebner JL, et al. Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability. Arthritis Res Ther. 2017;19:12. doi: 10.1186/s13075-016-1215-7.
    1. Novak ML, Koh TJ. Phenotypic transitions of macrophages orchestrate tissue repair. Am J Pathol. 2013;183:1352–1363. doi: 10.1016/j.ajpath.2013.06.034.
    1. Lightfoot AP, Cooper RG. The role of myokines in muscle health and disease. Curr Opin Rheumatol. 2016;28:661–666. doi: 10.1097/BOR.0000000000000337.
    1. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–465. doi: 10.1038/nrendo.2012.49.
    1. Rodriguez J, Vernus B, Chelh I, Cassar-Malek I, Gabillard JC, Hadj Sassi A, et al. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci. 2014;71:4361–4371. doi: 10.1007/s00018-014-1689-x.
    1. Rancourt A, Dufresne S, St-Pierre G, Lévesque J, Nakamura H, Kikuchi Y, et al. Galectin-3 and N-acetylglucosamine promote myogenesis and improve skeletal muscle function in the mdx model of Duchenne muscular dystrophy. FASEB J. 2018:fj201701151RRR.
    1. Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003;48:2788–2795. doi: 10.1002/art.11287.
    1. Forsman H, Islander U, Andréasson E, Andersson A, Onnheim K, Karlström A, et al. Galectin 3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum. 2011;63:445–454. doi: 10.1002/art.30118.
    1. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160–171. doi: 10.1111/j.1600-065X.2009.00794.x.
    1. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172:288–298. doi: 10.2353/ajpath.2008.070726.
    1. Issa SF, Christensen AF, Lottenburger T, Junker K, Lindegaard H, Hørslev-Petersen K, et al. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals. Scand J Immunol. 2015;82:70–75. doi: 10.1111/sji.12301.
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324. doi: 10.1002/art.1780310302.
    1. Bartlett DB, Willis LH, Slentz CA, Hoselton A, Kelly L, Heubner JL, et al. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. Arthritis Res Ther. 2018;20:127. doi: 10.1186/s13075-018-1624-x.
    1. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty eight- joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48. doi: 10.1002/art.1780380107.
    1. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35:609–616. doi: 10.3109/00365517509095787.
    1. AbouAssi H, Tune KN, Gilmore B, Bateman LA, McDaniel G, Muehlbauer M, et al. Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. J Rheumatol. 2014;41:1974–1979. doi: 10.3899/jrheum.140224.
    1. VassarStats: website for statistical computation. Vassar College. 1998–2015. . Accessed May 2017.
    1. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219–226. doi: 10.1161/CIRCHEARTFAILURE.112.000129.
    1. Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017;119:57–64. doi: 10.1016/j.amjcard.2016.09.019.
    1. Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J, et al. Impact of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since 2009. Prog Cardiovasc Dis. 2017;60:11–20. doi: 10.1016/j.pcad.2017.03.001.
    1. Lemmey AB, Wilkinson TJ, Clayton RJ, Sheikh F, Whale J, Jones HS, et al. Tight control of disease activity fails to improve body composition or physical function in rheumatoid arthritis patients. Rheumatology (Oxford) 2016;55:1736–1745. doi: 10.1093/rheumatology/kew243.
    1. Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12:R197. doi: 10.1186/ar3169.
    1. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84:1463–1472. doi: 10.1093/ajcn/84.6.1463.
    1. Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8:639–646. doi: 10.1002/jcsm.12189.
    1. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338–3342.
    1. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2006;12:6–33.
    1. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol. 2015;11:86–97. doi: 10.1038/nrrheum.2014.193.

Source: PubMed

3
Suscribir